4-[(2,3-dimethylcyclohexyl)methyl]-1H-imidazole | 2408662-26-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[(2,3-dimethylcyclohexyl)methyl]-1H-imidazole
• 英文别名: 5-[(2,3-dimethylcyclohexyl)methyl]-1H-imidazole
• CAS: 2408662-26-8
• 化学式: C₁₂H₂₀N₂
• 分子量: 192.3
• InChiKey: CGVPZYVYSKGFLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• DETOMIDINE HYDROCHLORIDE MONOHYDRATE
  申请人：Sachse, Andreas

  公开号：EP3782989A1

  公开（公告）日：2021-02-24

  The present invention relates to detomidine hydrochloride monohydrate, a method for the production of the same and to the use of the same as a medicament, that is for use as anesthetic, analgesic, muscle relaxant, sedative and any other condition susceptible to treatment with an alpha2-adrenoreceptor agonist in a mammal. Detomidine hydrochloride monohydrate described herein represents the pure monohydrate form which additionally shows a high purity reflected the very low content of impurities and especially residual solvents. Correspondingly, detomidine hydrochloride monohydrate described herein, shows a very high storage stability which is useful for the production of pharmaceutical compositions for the treatment of pathological conditions.

  本发明涉及盐酸地托咪定一水合物、盐酸地托咪定一水合物的生产方法以及盐酸地托咪定一水合物的药物用途，盐酸地托咪定一水合物可用作哺乳动物的麻醉剂、镇痛剂、肌肉松弛剂、镇静剂以及任何其他可接受α2-肾上腺素受体激动剂治疗的病症。 本文所述的盐酸地托咪定一水合物是纯净的一水合物，其高纯度反映了杂质，特别是残留溶剂的含量极低。相应地，本文所述的盐酸地托咪定一水合物显示出极高的储存稳定性，可用于生产治疗病症的药物组合物。
• [EN] PURIFIED CRYSTALLINE DETOMIDINE HYDROCHLORIDE MONOHYDRATE, ANHYDRATE AND FREE BASE WITH LOW AMOUNTS OF ISO-DETOMIDINE AND OTHER IMPURITIES BY RECRYSTALLISATION IN WATER<br/>[FR] CHLORHYDRATE DE DÉTOMIDINE MONOHYDRATÉ SOUS FORME CRISTALLINE PURIFIÉE, ANHYDRATE DE DÉTOMIDINE ET BASE LIBRE DE DÉTOMIDINE PRÉSENTANT DE FAIBLES QUANTITÉS D'ISO-DÉTOMIDINE ET D'AUTRES IMPURETÉS, OBTENUS PAR RECRISTALLISATION DANS L'EAU
  申请人：CLEXIO BIOSCIENCES LTD

  公开号：WO2020016827A4

  公开（公告）日：2020-03-19
• TOPICAL DETOMIDINE FORMULATIONS
  申请人：Clexio Biosciences Ltd.

  公开号：US20210220336A1

  公开（公告）日：2021-07-22

  The present disclosure relates to a purified detomidine HCl pharmaceutical product and to methods of preparation, validation of pharmaceutically acceptable product and use thereof.
• Purified Detomidine, Process of Preparing and Methods of Use
  申请人：Clexio Biosciences Ltd.

  公开号：US20210323929A1

  公开（公告）日：2021-10-21

  The present disclosure relates to a purified detomidine HCl pharmaceutical product and to methods of preparation, validation of pharmaceutically acceptable product and use thereof.
• [EN] DETOMIDINE HYDROCHLORIDE MONOHYDRATE<br/>[FR] MONOHYDRATE DE CHLORHYDRATE DE DÉTOMIDINE
  申请人：SACHSE ANDREAS

  公开号：WO2021037755A1

  公开（公告）日：2021-03-04

  The present invention relates to detomidine hydrochloride monohydrate, a method for the production of the same and to the use of the same as a medicament, that is for use as anesthetic, analgesic, muscle relaxant, sedative and any other condition susceptible to treatment with an alpha2- adrenoreceptor agonist in a mammal. Detomidine hydrochloride monohydrate described herein represents the pure monohydrate form which additionally shows a high purity reflected the very low content of impurities and especially residual solvents. Correspondingly, detomidine hydrochloride monohydrate described herein, shows a very high storage stability which is useful for the production of pharmaceutical compositions for the treatment of pathological conditions.